Cargando…

A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines

Safe, effective adjuvants that enhance vaccine potency, including induction of neutralizing Abs against a broad range of variant strains, is an important strategy for the development of seasonal influenza vaccines which can provide optimal protection, even during seasons when available vaccines are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coler, Rhea N., Baldwin, Susan L., Shaverdian, Narek, Bertholet, Sylvie, Reed, Steven J., Raman, Vanitha S., Lu, Xiuhua, DeVos, Joshua, Hancock, Kathy, Katz, Jacqueline M., Vedvick, Thomas S., Duthie, Malcolm S., Clegg, Christopher H., Van Hoeven, Neal, Reed, Steven G.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965144/ https://www.ncbi.nlm.nih.gov/pubmed/21060869 http://dx.doi.org/10.1371/journal.pone.0013677

Ejemplares similares

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
por: Coler, Rhea N., et al.
Publicado: (2011)

Optimizing Immunization Strategies for the Induction of Antigen-Specific CD4 and CD8 T Cell Responses for Protection against Intracellular Parasites
por: Hofmeyer, Kimberly A., et al.
Publicado: (2016)

Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy
por: Fox, Christopher B., et al.
Publicado: (2012)

Adjuvants for Leishmania vaccines: from models to clinical application
por: Raman, Vanitha S., et al.
Publicado: (2012)

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE
por: Coler, Rhea N, et al.
Publicado: (2015)

Improved Immune Responses in Young and Aged Mice with Adjuvanted Vaccines against H1N1 Influenza Infection
por: Baldwin, Susan L., et al.
Publicado: (2018)

Skin tests for the detection of Mycobacterial infections: achievements, current perspectives, and implications for other diseases
por: Duthie, Malcolm S., et al.
Publicado: (2021)

A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations
por: Van Hoeven, Neal, et al.
Publicado: (2016)

Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against Leishmania donovani
por: Duthie, Malcolm S., et al.
Publicado: (2018)

A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen
por: Van Hoeven, Neal, et al.
Publicado: (2018)

Strategic evaluation of vaccine candidate antigens for the prevention of Visceral Leishmaniasis
por: Duthie, Malcolm S., et al.
Publicado: (2016)

Radiotherapy: the key to immunotherapy ignition?
por: Luterstein, Elaine, et al.
Publicado: (2017)

A structure-function approach to optimizing TLR4 ligands for human vaccines
por: Carter, Darrick, et al.
Publicado: (2016)

Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model
por: Baldwin, Susan L., et al.
Publicado: (2021)

Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes
por: Fox, Christopher B, et al.
Publicado: (2014)

Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model
por: Kwon, Kee Woong, et al.
Publicado: (2019)

Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasis
por: Ghosh, Prakash, et al.
Publicado: (2016)

Truthfulness in patient-reported outcomes: factors affecting patients’ responses and impact on data quality
por: Chang, Eric M, et al.
Publicado: (2019)

Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs
por: Duthie, Malcolm S., et al.
Publicado: (2022)

Therapeutic efficacy against Mycobacterium tuberculosis using ID93 and liposomal adjuvant formulations
por: Baldwin, Susan L., et al.
Publicado: (2022)

Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis?
por: Larsen, Sasha E., et al.
Publicado: (2023)

A Dual TLR Agonist Adjuvant Enhances the Immunogenicity and Protective Efficacy of the Tuberculosis Vaccine Antigen ID93
por: Orr, Mark T., et al.
Publicado: (2014)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
por: Cauwelaert, Natasha Dubois, et al.
Publicado: (2016)

An RNA-Based Vaccine Platform for Use against Mycobacterium tuberculosis
por: Larsen, Sasha E., et al.
Publicado: (2023)

Abstract 1647: Quantification of functional antibody titers in a mouse model of SARS-CoV-2 infection
por: Hernandez, Dulce, et al.
Publicado: (2023)

Prevalence of Seropositivity to Pandemic Influenza A/H1N1 Virus in the United States following the 2009 Pandemic
por: Reed, Carrie, et al.
Publicado: (2012)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection
por: Erasmus, Jesse H., et al.
Publicado: (2020)

Optimizing manufacturing and composition of a TLR4 nanosuspension: physicochemical stability and vaccine adjuvant activity
por: Fung, HW Millie, et al.
Publicado: (2013)

Accurate Serodetection of Asymptomatic Leishmania donovani Infection by Use of Defined Antigens
por: Vallur, Aarthy C., et al.
Publicado: (2016)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140
por: Arias, Mauricio A., et al.
Publicado: (2012)

Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against Mycobacterium avium infection but is ineffective as an adjunct to antibiotic treatment in chronic disease
por: Lee, Ju Mi, et al.
Publicado: (2022)

The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases
por: Baldwin, Susan L., et al.
Publicado: (2019)

A defined subunit vaccine that protects against vector-borne visceral leishmaniasis
por: Duthie, Malcolm S., et al.
Publicado: (2017)

The single recombinant M. tuberculosis protein DPPD provides enhanced performance of skin testing among HIV-infected tuberculosis patients
por: Badaro, Roberto, et al.
Publicado: (2020)

It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity
por: Larsen, Sasha E., et al.
Publicado: (2022)

SARS-CoV-2 infection and immune responses
por: Harne, Rakhi, et al.
Publicado: (2023)

Expression Cloning of an Immunodominant Family of Mycobacterium tuberculosis Antigens Using Human Cd4(+) T Cells
por: Alderson, Mark R., et al.
Publicado: (2000)

Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development
por: Sampaio, Lucas H, et al.
Publicado: (2011)

Mycobacterium abscessus: It’s Complex
por: Abdelaal, Hazem F. M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tq1d2va67q2uv2ugn2dp659ti2